tetano
Editor, Senior Moderator
Lancet Infect Dis
. 2023 Jul 27;S1473-3099(23)00351-1.
doi: 10.1016/S1473-3099(23)00351-1. Online ahead of print. Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial
Isabel Leroux-Roels[SUP] 1 [/SUP], Paul Willems[SUP] 2 [/SUP], Gwenn Waerlop[SUP] 1 [/SUP], Yorick Janssens[SUP] 1 [/SUP], Jessika Tourneur[SUP] 2 [/SUP], Fien De Boever[SUP] 1 [/SUP], Jacques Bruhwyler[SUP] 3 [/SUP], Azhar Alhatemi[SUP] 1 [/SUP], Bart Jacobs[SUP] 1 [/SUP], Florence Nicolas[SUP] 2 [/SUP], Geert Leroux-Roels[SUP] 1 [/SUP], Alexandre Le Vert[SUP] 2 [/SUP]
Affiliations
Background: OVX836, a recombinant vaccine containing the nucleoprotein of the influenza A virus A/WSN/1933 (H1N1) and the oligomerisation domain OVX313, has displayed a good safety profile and elicited dose-dependent humoral and cellular immune responses at 90 μg or 180 μg (intramuscularly) in previous clinical trials. The aim of this study was to explore higher doses, since no maximum tolerated dose had been reached.
Methods: In this phase 2a, randomised, double-blind, placebo-controlled study, we recruited 137 healthy adults aged 18-55 years in a single centre in Belgium. Participants were randomly assigned (interactive web response system; block size=4) using SAS (version 9.4) to receive one single intramuscular administration of OVX836 influenza vaccine at three doses (180 μg [n=33], 300 μg [n=35], and 480 μg [n=36]) or placebo (n=33). The two primary endpoints were the safety and the cell-mediated immune response to OVX836 at the three doses in terms of change of nucleoprotein-specific IFNγ spot forming cell (SFC) frequencies in the peripheral blood mononuclear cell (PBMC) population, measured by IFNγ ELISpot, at day 8 versus pre-injection baseline (day 1). The population used for the safety analysis is the modified intention-to-treat cohort. The population used for the immunogenicity analysis is the per-protocol cohort. This trial is registered with ClinicalTrials.gov, NCT05060887, and EudraCT, 2021-002535-39.
Findings: Participants were recruited between Nov 15, 2021, and Feb 1, 2022. OVX836 had a favourable safety profile up to 480 μg without reaching the maximum tolerated dose, and showed a good safety profile at all doses with mild local and systemic reactogenicity. 7 days after vaccination, although no significant differences were observed between the doses, OVX836 increased the frequency of nucleoprotein-specific IFNγ SFCs per million PBMCs from days 1 to 8 (primary endpoint): by 124 SFCs per 10[SUP]6[/SUP] PMBCs (95% CI 67 to 180; p=0·002) at 180 μg; by 202 SFCs per 10[SUP]6[/SUP] PMBCs (95% CI 138 to 267; p<0·0001) at 300 μg; by 223 SFCs per 10[SUP]6[/SUP] PMBCs (95% CI 147 to 299; p<0·0001) at 480 μg; and decreased by 1 SFCs per 10[SUP]6[/SUP] PMBCs (95% CI -24 to 22] in the placebo group (Kruskal-Wallis test p<0·0001 followed by Mann-Whitney's tests; per-protocol cohort). Dose-dependent and polyfunctional nucleoprotein-specific CD4 T-cell responses were observed, and CD8 T-cell responses were elicited at 300 μg and 480 μg (secondary endpoints).
Interpretation: OVX836 appears to be a safe and well tolerated candidate vaccine that elicits humoral and cellular nucleoprotein-specific immune responses (including CD8 T cells at the highest dose levels) and showed a preliminary signal of protection against influenza. Therefore, OVX836 is a promising vaccine candidate for universal influenza A prevention, that warrants further trials.
Funding: OSIVAX, Bpifrance, Wallonia Region, and the EUs Horizon 2020 Research and Innovation Program.
. 2023 Jul 27;S1473-3099(23)00351-1.
doi: 10.1016/S1473-3099(23)00351-1. Online ahead of print. Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial
Isabel Leroux-Roels[SUP] 1 [/SUP], Paul Willems[SUP] 2 [/SUP], Gwenn Waerlop[SUP] 1 [/SUP], Yorick Janssens[SUP] 1 [/SUP], Jessika Tourneur[SUP] 2 [/SUP], Fien De Boever[SUP] 1 [/SUP], Jacques Bruhwyler[SUP] 3 [/SUP], Azhar Alhatemi[SUP] 1 [/SUP], Bart Jacobs[SUP] 1 [/SUP], Florence Nicolas[SUP] 2 [/SUP], Geert Leroux-Roels[SUP] 1 [/SUP], Alexandre Le Vert[SUP] 2 [/SUP]
Affiliations
- PMID: 37517422
- DOI: 10.1016/S1473-3099(23)00351-1
Background: OVX836, a recombinant vaccine containing the nucleoprotein of the influenza A virus A/WSN/1933 (H1N1) and the oligomerisation domain OVX313, has displayed a good safety profile and elicited dose-dependent humoral and cellular immune responses at 90 μg or 180 μg (intramuscularly) in previous clinical trials. The aim of this study was to explore higher doses, since no maximum tolerated dose had been reached.
Methods: In this phase 2a, randomised, double-blind, placebo-controlled study, we recruited 137 healthy adults aged 18-55 years in a single centre in Belgium. Participants were randomly assigned (interactive web response system; block size=4) using SAS (version 9.4) to receive one single intramuscular administration of OVX836 influenza vaccine at three doses (180 μg [n=33], 300 μg [n=35], and 480 μg [n=36]) or placebo (n=33). The two primary endpoints were the safety and the cell-mediated immune response to OVX836 at the three doses in terms of change of nucleoprotein-specific IFNγ spot forming cell (SFC) frequencies in the peripheral blood mononuclear cell (PBMC) population, measured by IFNγ ELISpot, at day 8 versus pre-injection baseline (day 1). The population used for the safety analysis is the modified intention-to-treat cohort. The population used for the immunogenicity analysis is the per-protocol cohort. This trial is registered with ClinicalTrials.gov, NCT05060887, and EudraCT, 2021-002535-39.
Findings: Participants were recruited between Nov 15, 2021, and Feb 1, 2022. OVX836 had a favourable safety profile up to 480 μg without reaching the maximum tolerated dose, and showed a good safety profile at all doses with mild local and systemic reactogenicity. 7 days after vaccination, although no significant differences were observed between the doses, OVX836 increased the frequency of nucleoprotein-specific IFNγ SFCs per million PBMCs from days 1 to 8 (primary endpoint): by 124 SFCs per 10[SUP]6[/SUP] PMBCs (95% CI 67 to 180; p=0·002) at 180 μg; by 202 SFCs per 10[SUP]6[/SUP] PMBCs (95% CI 138 to 267; p<0·0001) at 300 μg; by 223 SFCs per 10[SUP]6[/SUP] PMBCs (95% CI 147 to 299; p<0·0001) at 480 μg; and decreased by 1 SFCs per 10[SUP]6[/SUP] PMBCs (95% CI -24 to 22] in the placebo group (Kruskal-Wallis test p<0·0001 followed by Mann-Whitney's tests; per-protocol cohort). Dose-dependent and polyfunctional nucleoprotein-specific CD4 T-cell responses were observed, and CD8 T-cell responses were elicited at 300 μg and 480 μg (secondary endpoints).
Interpretation: OVX836 appears to be a safe and well tolerated candidate vaccine that elicits humoral and cellular nucleoprotein-specific immune responses (including CD8 T cells at the highest dose levels) and showed a preliminary signal of protection against influenza. Therefore, OVX836 is a promising vaccine candidate for universal influenza A prevention, that warrants further trials.
Funding: OSIVAX, Bpifrance, Wallonia Region, and the EUs Horizon 2020 Research and Innovation Program.